Table 2. Distribution of the TAS2R38 diplotype, CA6 rs2274333 genotype and the combined genotype.
| Total (n = 2,042)a | Case (n = 681) | Control (n = 1,361) | pchisqb | |
|---|---|---|---|---|
| TAS2R38 diplotype | ||||
| PAV/PAV | 726 (35.6) | 251 (36.9) | 475 (34.9) | 0.074 |
| PAV/AVI | 981 (48.0) | 337 (49.5) | 644 (47.3) | |
| AVI/AVI | 329 (16.1) | 92 (13.5) | 237 (17.4) | |
| AAV/AVI | 3 (0.15) | - | 3 (0.2) | |
| PAV/AVV | 1 (0.05) | 1 (0.2) | - | |
| PVI/AVI | 1 (0.05) | - | 1 (0.1) | |
| PVV/AVI | 1 (0.05) | - | 1 (0.1) | |
| PAV/PAV+PAV/AVIc | 1,707 (83.6) | 588 (86.5) | 1,119 (82.2) | 0.022 |
| CA6 rs2274333 | 0.009 | |||
| AA | 353 (17.3) | 142 (20.9) | 211 (15.5) | |
| GA | 957 (46.9) | 299 (43.9) | 658 (48.4) | |
| GG | 732 (35.9) | 240 (35.2) | 492 (36.2) | |
| GA + GGd | 1,689 (82.8) | 539 (79.1) | 1,150 (84.6) | 0.003 |
| Combined genotype (TAS2R38+CA6)e | 0.002 | |||
| PAV/*+AA | 288 (14.2) | 119 (17.5) | 169 (12.5) | |
| PAV/*+G* | 1,419 (69.7) | 469 (69.0) | 950 (70.1) | |
| AVI/AVI+AA | 65 (3.1) | 23 (3.3) | 42 (3.0) | |
| AVI/AVI+G* | 264 (13.0) | 69 (10.2) | 195 (14.4) |
a‘n’ indicates numbers of subjects.
bP-values from chi-square tests.
cComparison for the distribution of the recessive model (PAV/PAV+PAV/AVI versus AVI/AVI) by colorectal cancer phenotype.
dComparison for the distribution of the dominant model (AA versus GA+GG) by colorectal cancer phenotype.
eCombined genotype of recessive models for the TAS2R38 diplotype and dominant model for CA6 rs2274333, PAV/*+G*=[TAS2R38 (PAV/PAV+PAV/AVI)+CA6 (GA+GG)], AVI/AVI+G*=[TAS2R38 (AVI/AVI) + CA6 (GA+GG)], PAV/*+AA=[TAS2R38 (PAV/PAV+PAV/AVI)+CA6 (AA)] and AVI/AVI+AA=[TAS2R38 (AVI/AVI)+CA6 (AA)].